Ashton Thomas Private Wealth
CPRX icon

Ashton Thomas Private Wealth’s Catalyst Pharmaceutical CPRX Stock Holding History

Ashton Thomas Private Wealth’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-37,458
Closed -$1.18M – 1695
2026
Q2 		$1.18M Sell
37,458
-834
-2% -$24.6K 0.02% 517
2026
Q1 		$948K Buy
38,292
+23,611
+161% +$562K 0.02% 548
2025
Q4 		$343K Buy
14,681
+315
+2% +$7.02K 0.01% 776
2025
Q3 		$283K Sell
14,366
-1,645
-10% -$33.8K 0.01% 819
2025
Q2 		$347K Buy
16,011
+2,997
+23% +$70.7K 0.01% 648
2025
Q1 		$316K Buy
13,014
+899
+7% +$20.2K 0.01% 643
2024
Q4 		$253K Buy
12,115
+276
+2% +$5.93K 0.01% 681
2024
Q3 		$235K Buy
11,839
+84
+0.7% +$1.56K 0.01% 558
2024
Q2 		$182K Buy
11,755
+342
+3% +$5.32K 0.01% 586
2024
Q1 		$182K Buy
11,413
+1,014
+10% +$15.3K 0.01% 577
2023
Q4 		$175K Sell
10,399
-190
-2% -$2.6K 0.01% 562
2023
Q3 		$124K Buy
10,589
+190
+2% +$2.54K 0.01% 550
2023
Q2 		$140K Buy
+10,399
New +$150K 0.01% 558

Other funds holding CPRX

Allworth Financial
Allworth Financial Folsom, California $28.2B AUM 13.34% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Ashton Thomas Private Wealth's CPRX Position: Q3 2026 in Review

Ashton Thomas Private Wealth sold out of Catalyst Pharmaceutical (CPRX) in Q3 2026, closing a stake of 37,458 shares — an estimated $1.18M sold.

Ashton Thomas Private Wealth first reported a position in CPRX in Q2 2023 and held it in 13 quarters. The position peaked at $1.18M in Q2 2026. 2 funds tracked by Wall St. Rank hold CPRX as of Q3 2026.

  • Ashton Thomas Private Wealth reported no remaining Catalyst Pharmaceutical position as of Q3 2026 after selling out during the quarter.
  • Ashton Thomas Private Wealth sold 37,458 Catalyst Pharmaceutical shares in Q3 2026, an estimated $1.18M.
  • Ashton Thomas Private Wealth first reported a position in Catalyst Pharmaceutical in Q2 2023 and held it in 13 quarters.
  • Ashton Thomas Private Wealth's Catalyst Pharmaceutical position peaked at $1.18M in Q2 2026.
  • 2 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2026.

Based on Ashton Thomas Private Wealth's 13F filing for Q3 2026, filed 3 Nov 2026.